Lived experience backed by clinical research
Patient Experience Studies
Buvidal has been clinically proven to provide superior treatment satisfaction vs standard of care and to reduce the burden associated with daily medication³⁻⁵. In this section you can discover more about the experience Buvidal patients have reported as part of clinical research studies.
DEBUT Study
Treatment satisfaction with Buvidal has been investigated in the phase IV randomised, open-label, active-comparator, multicentre study Depot Evaluation–Buprenorphine Utilization Trial – DEBUT .
Patients receiving Buvidal had superior and significantly higher global treatment satisfaction scores than those receiving daily sublingual buprenorphine.
DEBUT Study
Barnett Study
A qualitative study exploring patient experiences of treatment with long-acting injectable buprenorphine revealed themes of reduced stigma and increased opportunities for social engagement.
It also pointed to the need to ensure meaningful routines are maintained without pharmacy attendance and that shared decision making was central to dose determination.
Barnett Study
Parsons Study
14 qualitative interviews were conducted with patients from treatment services in England and Wales seeking to document patient experiences of Buvidal.
12 out of the 14 patients reported progress toward recovery since initiating Buvidal.
Parsons Study
